This is the form of material change report required under Section 85(1) of the Securities Act.

BC FORM 51-102F3 (formerly Form 53-901F)

Securities Act

MATERIAL CHANGE REPORT UNDER SECTION 85(1) OF THE ACT

Item 1. Reporting Issuer

BlissCo Cannabis Corp. Suite2050 – 1055 West Georgia Street PO Box 11121, Royal Centre Vancouver, BC V6E 3P3

Item 2. <u>Date of Material Change</u>

April 2, 2018

Item 3. <u>Press Release</u>

April 2, 2018, at Vancouver, BC, Canada.

Item 4. <u>Summary of Material Change</u>

BlissCo Cannabis Corp. is pleased to announce that the Company's wholly-owned subsidiary, Bliss Co Holdings Ltd. ("BlissCo") has been granted a licence by Health Canada to cultivate cannabis plants and prepare dried cannabis.

Item 5. <u>Full Description of Material Change</u>

See attached press release.

Item 6. Reliance on Section 85(2) of the Act

N/A

Item 7. <u>Omitted Information</u>

None

Item 8. Senior Officers

The following senior officers of the Issuer are knowledgeable about the material change and may be contacted by the Commission at the address and telephone number:

Damian Kettlewell President, CEO & Director (778)840-8049 Praveen Varshney Director (604) 684-2181

Item 9. <u>Statement of Senior Officer</u>

The foregoing accurately discloses the material change referred to herein.

Dated this 2 nd day of April, 2018	"Praveen Varshney"	
	Praveen Varshney	
	Name	
	Director	
	Position / Title	
	Vancouver, B.C.	
	Place of Declaration	



Health Canada grants Cannabis Cultivation Licence to BlissCo

VANCOUVER, April 2, 2018 - BlissCo Cannabis Corp. (CSE: BLIS) ("BlissCo" or the "Company") is pleased to announce that the Company's wholly-owned subsidiary, Bliss Co Holdings Ltd. ("BlissCo") has been granted a licence by Health Canada to cultivate cannabis plants and prepare dried cannabis.

"Earning our ACMPR Licence to cultivate cannabis plants from Health Canada represents a significant milestone that the Company has been working towards for four and a half years," said the Company's Chief Executive Officer and Chair, Damian Kettlewell.

"Our ACMPR licence to cultivate allows us to execute on our strategic plan to build a distribution, brand and extraction focused cannabis company. We can now apply to expand our license to include cannabis oil production. At the appropriate time we will apply for a license to sell both dried cannabis and cannabis oil, from our own production and with premium dried cannabis sourced from our supply agreement. Considering our two-year supply agreement with The Supreme Cannabis Company Inc., (TSX.V: FIRE) for 3,000 kilograms of premium cannabis through June 2020, BlissCo is well positioned to generate revenue, subject to earning a license to sell.

We are grateful for the diligent and mindful work of our regulator and the steadfast support of our many industry partners and shareholders. BlissCo is excited to build an iconic Canadian cannabis brand from our base in Vancouver, B.C."

About BlissCo

BlissCo earned its *Access to Cannabis for Medical Purposes Regulation* ACMPR License to Cultivate on Thursday, March 29, 2018. BlissCo's ACMPR facility in Langley, B.C. is designed to be a high-volume packager, processor and distributor of medical cannabis and adult use cannabis when it is legal in Canada, which is currently anticipated to be by August 2018 at the earliest. BlissCo has a two year supply agreement with The Supreme Cannabis Company Inc. to purchase premium dried cannabis curated over the last two years from imported cannabis seeds.

BlissCo's will apply to expand its license to cannabis oil production in Q2 2018 and will apply for its cannabis sales license at the earliest appropriate time. BlissCo will focus on high volume sales opportunities in the regulated medical use and adult use cannabis market.

On Behalf of the Board of Directors

BLISSCO CANNABIS CORP.

Damian Kettlewell, CEO & Chair

Cautionary Statement

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively "forward-looking statements"). The use of any of the word "will" and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

For further information: Damian Kettlewell, CEO, 778 840 8049, damian.kettlewell@blissco.com